{"prompt": "['Product: MK-3475', '38', 'Protocol/Amendment No.: 604-09', '5.2 Trial Treatment(s)', 'The treatments to be used in this trial are outlined below in Table 2.', 'Table 2', 'Trial Treatments', 'Regimen/', 'Drug or', 'Dose/', 'Dose', 'Route of', 'Treatment', 'Biologic', 'Potency', 'Frequency', 'Administration', 'Period', 'Use', 'Pembrolizumab', '200 mg', 'Q3W', 'IV infusion', 'Day 1 of each', 'Experimental', 'cycle prior to', 'chemotherapy', 'Saline', 'Not', 'Q3W', 'IV infusion', 'Day 1 of each', 'Placebo', 'applicable', 'cycle prior to', 'comparator', 'chemotherapy', 'Carboplatin', 'AUC 5', 'Q3W', 'IV infusion', 'Day 1 of each', 'cycle', 'Cisplatin', '75 mg/m\u00b2', 'Q3W', 'IV infusion', 'Day 1 of each', 'Standard of', 'cycle', 'care', 'Etoposide', '100 mg/m\u00b2', 'Q3W', 'IV infusion', 'Days 1, 2, 3 of', 'each cycle', 'Trial treatment should begin on the day of randomization or as soon as possible, but no later', 'than 3 days after randomization.', 'All supplies indicated in Table 2 above will be provided centrally by the Sponsor or locally', 'by the trial site, subsidiary or designee, depending on local country operational or regulatory', 'requirements.', 'For any commercially available product that is provided by the trial site, subsidiary or', 'designee every attempt will be made to source these supplies from a single lot/batch number.', 'The trial site is responsible for recording the lot number, manufacturer, and expiry date for', 'any locally purchased product as per local guidelines unless otherwise instructed by the', 'Sponsor.', 'The investigator shall take responsibility for and shall take all steps to maintain appropriate', 'records and ensure appropriate supply, storage, handling, distribution and usage of trial', 'treatments in accordance with the protocol and any applicable laws and regulations.', '5.2.1', 'Dose Selection/Modification', '5.2.1.1 Dose Selection (Preparation)', 'Pembrolizumab: The amount required to prepare the pembrolizumab infusion solution will', 'be based on a fixed dose of 200 mg. Details on the preparation and administration are', 'provided in the Pharmacy Manual.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '39', 'Protocol/Amendment No.: 604-09', 'Standard chemotherapeutic agents (etoposide and carboplatin or cisplatin) will be prepared', 'and administered as per the local approved product label. Appropriate infusion times for each', 'agent are noted in the respective subsections of Section 5.2.2.2.', 'The rationale for selection of doses to be used in this trial is provided in Section 4.0.', '5.2.1.2 Dose Modification', 'If a subject experiences a >10% weight change during Cycles 1 to 4, the doses of etoposide', 'and cisplatin/carboplatin should be recalculated.', \"Dose modifications due to AEs will depend on the investigator's assessment of causality. If\", 'appropriate, the investigator may attribute each toxicity event to etoposide,', 'cisplatin/carboplatin, or pembrolizumab alone or to the combination and use a stepwise dose', 'reduction according to Table 3 through Table 7. Dose modifications must be based on the', 'maximum toxicity experienced during a cycle. Toxicity must resolve to Grade 1 or baseline', 'prior to resuming the subsequent cycle, with the exception of alopecia, Grade 2 fatigue,', 'endocrine-related AEs requiring treatment or hormone replacement, which may be Grade 2,', 'and creatinine clearance, for which the guidelines in Section 5.2.1.2.2 may be followed.', 'If a dose reduction for toxicity occurs with any agent, the dose may not be re-escalated.', 'Subjects can have a maximum of 2 dose modifications (if applicable) to each of the', 'components of study therapy throughout the course of the study for toxicities. If a subject', 'experiences several toxicities and there are conflicting recommendations, the most', 'conservative dose adjustment recommended should be followed (ie, dose reduction', 'appropriate to the most severe toxicity). Subjects who require a third dose modification to', 'any particular component will have that agent discontinued. In the absence of the agent', 'thought to be causing toxicity, treatment can continue with pembrolizumab or saline placebo', 'and the remaining chemotherapeutic drug.', 'Reduction of 1 chemotherapy agent and not the other agent is appropriate if, in the opinion of', 'the investigator, the toxicity is clearly related to one of the treatments. If, in the opinion of', 'the investigator, the toxicity is related to the combination of both chemotherapy agents, both', 'drugs should be reduced according to recommended dose modifications. If the toxicity is', 'related to the combination of 3 agents, all 3 agents should be reduced (if applicable),', 'interrupted, or discontinued according to the recommended dose modifications.', 'Pembrolizumab dose reductions are not permitted. Pembrolizumab treatment may be', 'delayed/interrupted for a maximum of 12 weeks or discontinued due to toxicity.', 'Subjects may have chemotherapy discontinued and continue on pembrolizumab or saline', 'placebo alone. Similarly, subjects may discontinue pembrolizumab or saline placebo and', 'continue on chemotherapy alone during the first 4 cycles, if appropriate. Any requests for', 'unblinding will be considered on an individual subject basis and only after consultation with', 'the Sponsor.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}